Emicizumab Prophylaxis in Hemophilia A with Inhibitors

被引：6
|
作者：
Aledort, Louis M. [1 ]
Ewenstein, Bruce M. [2 ]
机构：
[1] Icahn Sch Med, New York, NY 10029 USA
[2] Shire, Cambridge, MA USA
来源：
NEW ENGLAND JOURNAL OF MEDICINE | 2017年 / 377卷 / 22期
关键词：
D O I：
10.1056/NEJMc1712683
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：2193 / 2193
页数：1
相关论文
共 50 条
  • [31] Hemophilia A in infantsEffective prophylaxis with emicizumab possible at an early stage
    Burggraf, Leoni
    [J]. TRANSFUSION MEDICINE AND HEMOTHERAPY, 2023, 50 (05)
  • [32] CHANGES IN INHIBITORS AFTER RE-EXPOSURE TO FACTOR VIII CONCENTRATE DURING EMICIZUMAB PROPHYLAXIS IN CHILDREN WITH HEMOPHILIA A WITH INHIBITORS
    Kodera, Asami
    Sato, Atsushi
    Hayasaka, Hiroe
    Ogawa, Maki
    Nanjo, Yuka
    Suzuki, Tasuku
    Suzuki, Nobu
    Onuma, Masaei
    Rikiishi, Takeshi
    Imaizumi, Masue
    [J]. PEDIATRIC BLOOD & CANCER, 2024, 71 : S101 - S102
  • [33] Emicizumab use in females with moderate or mild hemophilia A without factor VIII inhibitors who warrant prophylaxis
    Hermans, Cedric
    Ventriglia, Giuliana
    Obaji, Samya
    Beckermann, Benjamin M.
    Lehle, Michaela
    Catalani, Olivier
    d'Oiron, Roseline
    Frenzel, Laurent
    [J]. RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS, 2023, 7 (08)
  • [34] Hemlibra® (Emicizumab) receives EU Approval for Routine Prophylaxis of Hemophilia A with Inhibitors against Coagulation Factor VIII
    不详
    [J]. TRANSFUSION MEDICINE AND HEMOTHERAPY, 2018, 45 (02)
  • [35] Longitudinal dynamic changes in factor VIII inhibitor titers in patients with hemophilia A and inhibitors receiving emicizumab prophylaxis
    Shimonishi, Naruto
    Sasai, Kana
    Ogiwara, Kenichi
    Furukawa, Shoko
    Nakajima, Yuto
    Mizumachi, Kuniyoshi
    Yada, Koji
    Takeyama, Masahiro
    Shima, Midori
    Mizuno, Narumi
    Nogami, Keiji
    [J]. INTERNATIONAL JOURNAL OF HEMATOLOGY, 2023, 118 (06) : 690 - 698
  • [36] BUDGET IMPACT ANALYSIS OF THE USE OF EMICIZUMAB IN PROPHYLAXIS FOR SEVERE HEMOPHILIA A AND INHIBITORS IN THE PEDIATRIC COPULATION OF THE DOMINICAN REPUBLIC
    Munoz, A.
    Bustamante, A.
    Blanco, J.
    [J]. VALUE IN HEALTH, 2022, 25 (12) : S135 - S136
  • [37] Longitudinal dynamic changes in factor VIII inhibitor titers in patients with hemophilia A and inhibitors receiving emicizumab prophylaxis
    Naruto Shimonishi
    Kana Sasai
    Kenichi Ogiwara
    Shoko Furukawa
    Yuto Nakajima
    Kuniyoshi Mizumachi
    Koji Yada
    Masahiro Takeyama
    Midori Shima
    Narumi Mizuno
    Keiji Nogami
    [J]. International Journal of Hematology, 2023, 118 : 690 - 698
  • [38] Emicizumab prophylaxis and health-related outcomes in persons with hemophilia a (PwHA) with inhibitors: HAVEN 1 study
    Oldenburg, J.
    Mahlangu, J. N.
    Bujan, W.
    Trask, P. C.
    von Mackensen, S.
    Callaghan, M. U.
    Young, G.
    Asikanius, E.
    Peyvandi, F.
    Santagostino, E.
    Kruse-Jarres, R.
    Negrier, C.
    Kessler, C.
    Levy, G. G.
    Windyga, J.
    Shima, M.
    [J]. HAEMOPHILIA, 2018, 24 : 89 - 90
  • [39] Emicizumab prophylaxis among infants and toddlers with severe hemophilia A and inhibitors-a single-center cohort
    Barg, Assaf A.
    Avishai, Einat
    Budnik, Ivan
    Levy-Mendelovich, Sarina
    Barazani, Tami B.
    Kenet, Gili
    Livnat, Tami
    [J]. PEDIATRIC BLOOD & CANCER, 2019, 66 (11)
  • [40] Efficacy and safety of prophylaxis with emicizumab in hemophilia A: A study of 13 patients
    Gomez, M. Angeles Ocana
    Machin, Alejandro Ferrer
    Cabrera, Martin Vera
    Tosco, Karen Ilenia Alvarez
    De Paz, Mario Rios
    Garcia, Dolores De Dios
    [J]. MEDICINA CLINICA, 2024, 162 (03): : 134 - 137
12345